A Pharmacokinetic Study of AC480 Administered Twice Daily in Surgically Resectable Malignant Glioma Patients Not on Enzyme-Inducing Anticonvulsants.

Trial Profile

A Pharmacokinetic Study of AC480 Administered Twice Daily in Surgically Resectable Malignant Glioma Patients Not on Enzyme-Inducing Anticonvulsants.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jan 2014

At a glance

  • Drugs BMS 599626 (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
  • Focus Pharmacokinetics
  • Most Recent Events

    • 28 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials/gov record.
    • 18 Sep 2012 Planned end date changed from 1 Jun 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 21 Feb 2012 Planned end date changed from 1 Nov 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top